Copy the shared link
As AI and machine learning transform entire sectors of the economy, there’s a rising demand for automated diagnostic solutions in the health industry. Already, the AI in healthcare market is worth $11 billion worldwide, which is expected to reach $188 billion by 2030. Spearheaded by institutions that want to streamline diagnostics, saving time and resources, innovative new systems are being trialed and adopted.
NOUL‘s launch of the miLab™ BCM in the European market is at the forefront of this shift. It marks a major milestone for the company and presents an opportunity for European nations to improve testing efficiency, addressing significant challenges like aging populations and limited healthcare infrastructure.
With miLab™ BCM showing breakthroughs in early blood cancer detection, NOUL is ready to expand its impact on precision diagnostics.
NOUL’s Expansion into Italy
Source : Freepik
Italy is a prime market for NOUL. The nation has a significant aging population problem alongside a health sector that’s always looking for innovative solutions. Italy presented the first European sales case of the miLab™ BCM after the earlier adoption of the miLab™ MAL.
Despite offering some of the world’s best healthcare, Italy’s elderly population is growing year on year. Between 2009 and 2024, it grew from 20.3% to 24.3% and is expected to continue this trend. Pressure on the healthcare system often comes in the form of routine blood tests, as older adults undergo more checkups per capita than the younger population.
Recognizing these challenges, NOUL has responded with biotechnological innovations and automated diagnostics that streamline testing processes. The integration of AI and digitalization into NOUL‘s diagnostic solutions not only enhances testing efficiency but also improves accuracy, catering to the increased demand.
NOUL was proud to offer the perfect solution and is in ongoing negotiations with other major European healthcare institutions to expand further. Learn more about NOUL’s expansion into Europe here.
miLab™ BCM’s Technological Innovations
Source : NOUL
What sets the miLab™ BCM apart? As biological innovations go, it’s at the cutting edge of microscopy, AI and digitalization, and automated diagnostics. Here are some of the ingenious features:
- Automated Precision. The new platform enhances traditional PBS testing capabilities with a fully automated system, offering an alternative for improved efficiency. The blood sample is inserted into the machine, which then analyses the problem, providing a high-level diagnosis.
- Remarkable Technology. After you’ve inserted a blood sample, the built-in camera takes high-quality digital imaging. These images are then analyzed by the AI to identify any morphological changes in the blood cells. Any changes are documented as part of the platform’s report.
- Scalability. Instead of waiting for new specialists to be trained, miLab™ BCM‘s platform can be rapidly expanded to deal with hundreds of tests per day. Each machine is easy to use – perfect for healthcare settings with minimal infrastructure.
- Labor-Saving. Compared to traditional blood tests, where patients are waiting hours or days for their results, miLab™ BCM‘s efficient workflow delivers results in just minutes.
- POCT Applicability. For decentralized labs with lower test volumes, the miLab™ BCM excels as a Point-of-Care Testing (POCT) solution. Its compact and user-friendly design makes it ideal for settings where traditional, centralized labs are impractical, ensuring both accessibility and efficient diagnostics in low-volume environments.
In addition to these innovations, the miLab™ BCM doesn’t just provide the same details you’d expect from the average blood test; it has the potential to improve early detection of blood cancers like leukemia by leveraging AI-driven morphological analysis.
Global Market Dynamics and Trends
Source : Freepik
According to a report by Grand View Research, the global blood testing market was valued at approximately $96.62 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.83% from 2025 to 2030. The driving force behind this change isn’t conventional testing but the rising interest in biotechnological innovations, namely AI and digitalization and automated diagnostics.
With increasing pressure on healthcare systems in middle- and high-income countries, finding more efficient diagnostic solutions is crucial to providing the same level of care on a smaller budget. That means healthcare institutions can shift current spending towards other high-demand areas like chronic diseases or geriatric care.
miLab™ BCM represents a revolutionary advancement, poised to replace around 680 million peripheral blood smear tests conducted globally each year. Where the miLab™ BCM is particularly effective is in regions facing limited resources. That could be poorer European regions, like southern Europe, or developing nations. Its initial upfront costs are a fraction of what would usually be spent on a new blood testing lab. Let alone training and employing the team to run it.
Regulatory Approvals and Future Directions
Source : Freepik
Part of the challenge for NOUL is navigating each nation’s regulatory framework. The company has secured regulatory approvals in key regions including Europe, ASEAN, the Middle East, and Korea for specific diagnostic applications. The Korean market, in particular, was a key milestone as it represents an expansion into NOUL‘s domestic market, increasing local credibility.
The next step is the United States, where NOUL is pushing for FDA approval. Securing FDA approval is a complex process that NOUL is actively pursuing, focusing on aligning its automated diagnostic solutions for blood cancers with U.S. regulatory requirements. This approval is critical for accessing significant market opportunities. By targeting underserved areas and addressing diverse healthcare challenges, the company can expand its global presence.
The recent approval of miLab™ BCM for blood cancer diagnostics showcases NOUL‘s innovation. This development enhances the company’s diagnostic range, highlighting its growing importance in oncology. With this approval, NOUL is set to revolutionize blood cancer diagnosis and management, improving both accuracy and efficiency.
Kim Tae-Hwan, NOUL‘s Chief Business Officer (CBO), commented, “With this regulatory approval, we aim not only to penetrate the domestic market but also to expedite global regulatory processes, including FDA approval in the United States. Our goal is to enhance trust in major overseas markets, such as the US and Europe.”
Conclusion
NOUL‘s expansion into European market is a landmark shift both for the company and the continent. With Europe’s healthcare systems dealing with aging populations, it’s increasingly looking for labor- and resource-saving diagnostic solutions to streamline its current system.
The miLab™ BCM represents an obvious solution. Harnessing the power of AI and digitalization, it represents the next stage in automated diagnostics. We’re confident that institutions that adopt our systems will see an increase in efficiency equal to or better than many previous biotechnological innovations.
Learn more about miLab™ BCM‘s benefits and explore how you can adopt this cutting-edge technology. Discover how miLab™ BCM can transform your facility’s diagnostic capabilities—contact us today to learn more!
